# Lunit vs RapidAI

Lunit records 29,181 monthly visits with -12.8% month-over-month growth and Contact for Pricing pricing. RapidAI records 20,172 monthly visits with -27.9% growth and Contact for Pricing pricing.

| Metric | [Lunit](https://openaitools.app/tool/lunit) | [RapidAI](https://openaitools.app/tool/rapidai-com) |
| :--- | :--- | :--- |
| Website URL | https://www.lunit.io/en | https://rapidai.com |
| Categories | AI Healthcare, AI Medical Diagnosis, AI Image Recognition | AI Medical Diagnosis, AI Healthcare, AI Detector, AI Image Recognition |
| Pricing Model | Contact for Pricing | Contact for Pricing |
| Monthly Visits | 29,181 | 20,172 |
| MoM Growth Rate | -12.8% | -27.9% |
| Primary Market | South Korea | United States |
| Direct Visits | 8,314 | 9,047 |
| Review Score | 4.6 | 4.6 |
| Saved Count | 1 | 0 |
| Supported Platforms | Website | Website |

## Lunit

Lunit is a medical AI company headquartered in Seoul, South Korea, spun out of deep-learning research and focused squarely on oncology. Rather than chasing general-purpose healthcare AI, it has built two connected product families: one that helps clinicians find cancer earlier in imaging, and one that extracts quantitative biology from tissue to guide treatment and drug development. Its technology is used across a large international footprint spanning more than 10,000 customer sites in over 70 countries, with hundreds of peer-reviewed publications and industry partnerships behind the deployments.

On the screening side, the Lunit INSIGHT family analyzes mammograms and chest radiographs. Lunit INSIGHT MMG handles 2D mammography while Lunit INSIGHT DBT covers 3D breast tomosynthesis, both designed to flag suspicious regions so radiologists can prioritize the studies that need attention most. Lunit INSIGHT CXR does the same for chest X-rays. Around these detection engines Lunit has assembled program-level tooling: density assessment, risk assessment and risk pathways, live mammography reporting, quality management, analytics, and a patient hub, so a screening service can run AI as part of its routine rather than as an isolated experiment.

On the precision oncology side, the Lunit SCOPE portfolio analyzes pathology images. Lunit SCOPE IO quantifies the tumor microenvironment and immune cell infiltration, which matters for immunotherapy strategy, while the Lunit SCOPE IHC Suite supports immunohistochemistry quantification across markers such as HER2 and PD-L1, alongside a genotype prediction tool. These products are aimed at biopharma partners, clinical trial teams, and companion diagnostic development, where reproducible quantitative readouts are the bottleneck. Because Lunit sells to hospitals, screening programs, and pharmaceutical companies, pricing is quoted directly rather than published, and regulatory status differs by market.

**Pricing & Plans:** Contact for pricing. Lunit sells enterprise software and platform licenses to hospitals, screening programs, and biopharma partners, so commercial terms and deployment costs are quoted directly through its sales team. No public price list is offered.

- **Lunit INSIGHT MMG and DBT:** Deep-learning analysis of 2D and 3D mammography that marks suspicious lesions to help radiologists detect breast cancer earlier and reduce missed findings.
- **Lunit INSIGHT CXR:** Chest X-ray analysis that highlights potential abnormalities such as nodules and other findings, supporting faster triage in high-volume radiology workflows.
- **Lunit SCOPE IO:** Tumor microenvironment analysis that quantifies tumor-infiltrating lymphocytes and immune phenotypes from pathology slides, informing immunotherapy research.
- **Lunit SCOPE IHC Suite:** AI-assisted immunohistochemistry quantification covering HER2, PD-L1, and other markers, including uIHC and a gene-expression prediction tool for standardized scoring.
- **Screening analytics and workflow tools:** Live mammography reporting, risk assessment, risk pathways, quality management, and patient-facing tools that embed AI into the wider screening program.

**Strengths:** Clinically validated radiology AI with documented regulatory clearances and published evidence; Covers two ends of the cancer pathway — screening detection and precision oncology biomarkers — in one vendor relationship; Wide real-world adoption across many countries, which means integrations and workflow lessons already exist; Strong research output and biopharma partnerships support credibility for trial and CDx work

[Profile (Markdown)](https://openaitools.app/tool/lunit.md)

## RapidAI

RapidAI grew out of stroke imaging research and has become one of the most widely deployed clinical AI platforms in healthcare. Its core promise is speed: when a large vessel occlusion or aneurysm is present, minutes matter, and RapidAI automatically detects, quantifies and communicates those findings to the treating team so decisions can be made sooner. Beyond neuro, the platform spans cardiac and vascular, trauma and emergency, oncology and radiology support workflows, all delivered through a single enterprise layer.

The Rapid Enterprise platform is built for scale rather than single-department pilots. It combines deep clinical AI with workflow integration, secure enterprise infrastructure, analytics dashboards and the ability to plug in partner AI models. That means a health system can standardize on one vendor-agnostic platform, connect imaging to action across service lines, and give administrators the visibility they need to track utilization and impact.

Adoption is aimed squarely at organizations, not individuals. Hospitals and radiology groups typically start with a demo request, then go through implementation and clinician education via RapidU before running the tools in production. The company reports FDA-cleared solutions, use in more than 2,500 hospitals globally and a publication library of over 750 peer-reviewed studies supporting its algorithms.

**Pricing & Plans:** Pricing is custom and quote-based; RapidAI does not publish a public price list. Interested organizations request a demo and discuss solution scope and licensing directly with the sales team.

- **Deep clinical AI across the body:** Detection and quantification algorithms for ischemic stroke, aneurysm, neurocritical care, aortic and pulmonary conditions, fractures, critical chest findings and lung, breast and prostate oncology.
- **Workflow integration:** Connect radiology, specialists and care teams with shared imaging insights so results reach the right clinician faster.
- **Enterprise infrastructure:** Vendor-agnostic, enterprise-grade infrastructure with healthcare-grade security and compliance that scales across a health system.
- **Data and analytics:** Visibility into utilization, performance and clinical impact so administrators can measure and optimize outcomes.
- **Integrated partner AI:** Access trusted third-party clinical AI models through the Rapid Enterprise platform alongside RapidAI's own solutions.

**Strengths:** Broad portfolio of FDA-cleared clinical AI algorithms in one platform; Designed for enterprise-wide deployment instead of isolated pilots; Strong validation base with 750+ peer-reviewed studies; Vendor-agnostic integration and 24/7 support

**Limitations:** Enterprise sales model with no self-serve signup or public pricing; Clinicians must complete training before using the tools in live care settings; Requires integration with existing PACS/IT infrastructure for full value; Only relevant to healthcare organizations; no consumer or individual use

[Profile (Markdown)](https://openaitools.app/tool/rapidai-com.md)

## Frequently Asked Questions

### How do Lunit and RapidAI compare in monthly traffic?

Lunit has 29,181 monthly visits, while RapidAI has 20,172. Traffic estimates describe audience size, not product quality.

### How do their growth rates compare?

Lunit has a month-over-month growth rate of -12.8%; RapidAI has -27.9%.

### How does pricing compare?

Lunit: Contact for Pricing. Contact for pricing. Lunit sells enterprise software and platform licenses to hospitals, screening programs, and biopharma partners, so commercial terms and deployment costs are quoted directly through its sales team. No public price list is offered. RapidAI: Contact for Pricing. Pricing is custom and quote-based; RapidAI does not publish a public price list. Interested organizations request a demo and discuss solution scope and licensing directly with the sales team.

## Alternatives

| # | Tool Name | Monthly Visits | MoM Growth Rate | Pricing Model | Summary | Profile (Markdown) |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 1 | [Dr.Oracle](https://openaitools.app/tool/dr-oracle) | 723,847 | -1.2% | Free Trial | Guideline-directed medical answers with citations, built for clinicians | [.md](https://openaitools.app/tool/dr-oracle.md) |
| 2 | [ScanSkinAI](https://openaitools.app/tool/scanskinai) | 265,770 | -10.9% | Freemium, Paid | Free AI skin and mole scanning with optional dermatologist review | [.md](https://openaitools.app/tool/scanskinai.md) |
| 3 | [Overjet](https://openaitools.app/tool/overjet-ai) | 256,150 | +12.6% | Contact for Pricing | FDA-cleared dental AI for diagnostics, imaging, and insurance workflow | [.md](https://openaitools.app/tool/overjet-ai.md) |
| 4 | [Pearl](https://openaitools.app/tool/hellopearl-com) | 221,155 | -7.6% | Contact for Pricing | FDA-cleared dental AI for sharper diagnosis and a smoother front office | [.md](https://openaitools.app/tool/hellopearl-com.md) |
| 5 | [0xmd](https://openaitools.app/tool/0xmd-com) | 128,262 | -2.2% | Freemium | Generative AI for medical and everyday health questions | [.md](https://openaitools.app/tool/0xmd-com.md) |
| 6 | [CT Read](https://openaitools.app/tool/ct-read) | 103,157 | -5.8% | Paid | AI analysis that turns X-rays, CT scans, MRI and ultrasound into plain-language reports | [.md](https://openaitools.app/tool/ct-read.md) |
| 7 | [Glass Health](https://openaitools.app/tool/glass-health) | 41,068 | -52.2% | Contact for Pricing | Frontier clinical AI grounded in leading medical evidence | [.md](https://openaitools.app/tool/glass-health.md) |
| 8 | [Oatmeal Health](https://openaitools.app/tool/oatmeal-health) | 40,264 | -44.9% | Contact for Pricing | AI lung cancer screening that finds eligible patients and scores every nodule | [.md](https://openaitools.app/tool/oatmeal-health.md) |
| 9 | [Healz.AI](https://openaitools.app/tool/healz-ai) | 12,433 | -47.4% | Freemium, Free Trial, Paid | AI case review for cancer and complex conditions, with human oncologists in the loop | [.md](https://openaitools.app/tool/healz-ai.md) |
| 10 | [Ibex Medical Analytics](https://openaitools.app/tool/ibex-ai-com) | 9,117 | -3% | Contact for Pricing | AI-powered cancer diagnostics that help pathologists detect disease earlier and more accurately. | [.md](https://openaitools.app/tool/ibex-ai-com.md) |

---
Source: https://openaitools.app/compare/lunit-vs-rapidai-com

More Markdown: [Categories](https://openaitools.app/categories.md) · [Traffic rankings](https://openaitools.app/rankings.md) · [llms.txt](https://openaitools.app/llms.txt)
